Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells

International Archives of Allergy and Immunology

Volumn 111, Issue 1, 1996, Pages 23-29

  Patella, Vincenzo ^a   De Crescenzo, Gennaro ^a   Marino, Oreste ^a   Spadaro, Giuseppe ^a   Genovese, Arturo ^a   Marone, Gianni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Basophils; Histamine; Leukotriene C4; Mast Cells; Oxatomide; Prostaglandin D2

Indexed keywords

HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; LEUKOTRIENE C4; MONOCLONAL ANTIBODY; OXATOMIDE; PROSTAGLANDIN D2; TRYPTASE;

ADULT; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BASOPHIL; CELL SECRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HISTAMINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG PARENCHYMA; MAST CELL; NORMAL HUMAN; PRIORITY JOURNAL; SKIN ALLERGY;

EID: 0029808063     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237340     Document Type: Article

References (57)

1. Marone G: Human Basophils and Mast Cells. Biological Aspects. Karger. Basel. 1995.
2. Marone G: Human Basophils and Mast Cells. Clinical Aspects. Karger. Basel. 1995.
3. Patella V, Casolaro V, Ciccarelli A, Pettit GR, Columbo M, Marone G: The antineoplastic hryostatins afl'cct differently human basophils and mast cells. Blood 1995;85:1272-1281.
4. Patella V, Marino I, Lamparter B, Arbustini E, Adt M, Marone G: Human heart mast cells. Isolation. purification, ultrastructurc and immunologic characterization. J Immunol 1995:154: 2855-2865.
5. Hide M, Franeis DM, Grattan CEH, Ilakimi J, Kochan JP, Greaves MW: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328:1599-1604.
6. Nawata Y, Koike T, Yanagisawa T, Iwamoto I, Itaya T, Yoshida S, Tomioka H: Anti-lgE autoantibody in patients with bronchial asthma. Clin Exp Immunol 1984:58:348-356.
7. Nawata Y, Koike T, Hosokawa H, Tomioka H, Yoshida S: Anti-lgE autoantibody in patients with atopic dermatitis. J Immunol 1985; 135: 478-482.
8. Quinti I, Brozek C, Wood N, Geha RS, Leung DYM: Circulating IgG autoantibodies to IgE in atopic syndromes. J Allergy Clin Immunol 1986:77:586-594.
9. Gruber BL, Baeza ML, Marchese MJ, Agnello V: Prevalence and functional role of anti-lgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988:90:213-217.
10. Marone G, Casolaro V, Paganelli R, Quinti I: IgG anti-lgE from atopic dermat-itis induces mediator release from basophils and mast cells. J Invest Dermatol 1989:93:246.
11. Grattan CEIL, Francis DM, Hide M, Greaves MW: Detection of circulating histamine releasing autoantibodies with functional propertiesof anti-lgE in chronic urticaria. Clin Exp Allergy 1991:21:695-04.
12. Czech W, Stadler BM, Schopf E, Kapp A: IgE autoantibodies in atopic dermatitis Occurrence of different antibodies against the CH3 and Cl 14 epitopes of IgE. Allergy 1995:50: 243-248.
13. Triggiani M, Oriente A, de Crescenzo G, Marone G: Metabolism of lipid mediators in human basophils and mast cells: in Marone G, (ed): Human Basophils and Mast Cells. Biological Aspects. Karger. Basel. 1995. p 135.
14. Triggiani M, Casolaro V, Genovese A, Spadaro G, Marone G: Heterogeneity of human Fet RI-bcaring cells. Ann Allergy 1993:71:133-138.
15. Benyon RC, Lowtnan MA, Church MK: Human skin mast cells: Their dispersion, purification. and secretory characterization. J Immunol 1987:138:861-867.
16. Stellato C, de Paulis A, Ciccarelli A, Cirillo R, Patella V, Casolaro V, Marone G: Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992:98:800-804.
17. Liu MC, Hubbard WC, Proud D, Stealey BA, Galli SJ, Kagey-Sobotka A, Bleecker ER, Lichtenstein LM: Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular. mediator, permeability, changes. Am Rev RespirDis 1991:144:51-58.
18. Koshino T, Teshima S, Fukushima N, Takaihi T, Ilirai K, Miyamoto Y, Arai Y, Sano Y, Ito K, Morita Y: Identification of basophils by iminu-nochemistry in the airways of post-mortem cases of fatal asthma. Clin Exp Allergy 1993: 23:919-925.
19. Guo CB, Liu MC, Galli SJ, Bochner BS, Ka-gey-Sobotka A, Lichtenstein LM: Identification of IgE-bcaring cells in the late-phase response to antigen in the lung as basophils. Am J RcspirCell Mol Biol 1994:10:384-390.
20. Galli SJ: New concepts about the mast cell. N Engl J Med 1993:328:257-265.
21. De Beule R, Vannieuwenhuyse E, Callier J, Ver-straete W, Degreel F, Gregoire M, Robicnce Y, Stevens W, Libert P: Double-blind placebo-controlled clinical evaluation of oxatoniide (R35443): A novel potent anti-allergic drug in the treatment of hay fever. Acta Allergol (C'o-penh) 1977:32:278-289.
22. Wood SF, Barber JH: Oxatoniide in the management of hay fever A placebo-controlled double-blind study in general practice. Clin Allergy 1981:11:491-497.
23. D’Amato G, Liccardi G, Cicchino G, Lobefalo G: Studio doppio cicco oxatomide vs placebo nelle rinocongiuntiviti allergiche stagionali. Giorn It Allergol Immunol Clin 1992:2:151-156
24. Gatti S, Coutts A, Francis D, Greaves MW: Oxatomide: In vitro assessment of antagonistic activity, and effects on histamine release and enzymatic histamine degradation in skin. Br J Dermatol 1980;103:671-677.
25. Pigatto PD, Nicora M, Altomare GF, Morelli M, Finzi AF: L’oxatomide nel trattamento dell'orticaria cronica: valutazione di efficacia e tollerabilità. Giom It Derm Vener 1987:122:25-32.
26. Peccini F, Nicora M, Bruni B, Dottrini ML, Grassi V: L’ oxatomide nella terapia dell'asma estrinseco dell’adulto. Min Pncum 1988:27: 185-194
27. Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS: Oxatomide a review of its pharmacodynamic properties and therapeutic efficacy. Drags 1984:27:210-231.
28. Ohmori K, Islth H, Kubota T, Shuto K, Nakami-zo N: Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea-pigs and rats. Arch hit Pharmacodyn 1985:275:139-150.
29. Piacentini GL, Peroni DG, Sette L, Bonizzato C, Benedetti M, Boner AL: Inhibition of different dosages of oxatoniide or placebo on skin prick test and nasal allergen provocation. J Allergy Clin Immunol 1991:88:218-225.
30. Van Receipts J, De Clerck F, Borgers M: Oxatomide protects against degranulation of rat peritoneal mast cells during in vitro challenge with antigen or compound 48/80. Ultrastructu-ral aspects. Agents Actions 1981:11:177-183.
31. De Clerck F, Van Reempts J, Borgers M: Comparative effects of oxatomide on the release of histamine from rat peritoneal mast cells. Agents Actions 1981:11:184-192.
32. Truneh A, White JR, Pearce FL: Effect of keto-tifcn and oxatoniide on histamine secretion from mast cells. Agents Actions 1982;12:206-209.
33. Tasaka K, Akagi M, Mio M, Miyoshi K, Nakaya N: Inhibitory effects of oxatoniide on intracel-lularCa mobilization. Ca uptake and histamine release, using rat peritoneal mast cells. Int Arch Allergy Appl Immunol 1987:83:348-353.
34. Choi SH, Sakamoto T, Fukutomi O, Inagaki N, Matsuura N, Nagai H, Koda A: Pharmacological study of phospholipase A-induccd histamine release from rat peritoneal mast cells. J Pharmacobiodyn 1989:12:517-522.
35. Church MK, Gradidge CF: Oxatomide: Inhibition and stimulation of histamine release from human lung and leucocytes in vitro. Agents Actions 1980:10:4-7.
36. Riske F, Llakimi J, Mallamaci M, Griffin M, Pil-son J, Tobkes N, Lin P, Danho W, Kochan J, Chizzonite R: High affinity human IgE receptor (FcfRI). Analysis of functional domains of theu-subunit with monoclonal antibodies. J Biol Chem 1991:266:11245-11251.
37. Columbo M, Bochncr BS, Marone G: Human skin mast cells express functional β1-integritis that mediate adhesion to extracellular matrix proteins. J Immunol 1995:154:6054-6064.
38. de Paulis A, Cirillo R, Ciccarelli A, de Crescenzo G, Oriente A, Marone G: Characterization of the antiinflammatory effect of FK-506 on human mast cells. J Immunol 1991; 147:4278-4285.
39. 4 release. J Pharmacol F.xpThcr 1992;263:979-986.
40. de Boer M, Roos D: Metabolic comparison between basophils and other leukocytes from human blood. J Immunol 1986:136:3447-3451.
41. Triggiani M, Oriente A, Marone G: Differential roles for triglyceride and phospholipid pools of arachidonie acid in human lung macrophages. J Immunol 1994:152:1394-1403.
42. Stellato C, Cirillo R, de Paulis A, Casolaro V, Patella V, Mastronardi P, Mazzarella B, Marone G: Human basophil inast cell rcleasability. IX. Heterogeneity of the cflcc's of opioids on mediator release. Anesthesiology 1992:77: 932-940.
43. Siraganian RP: An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 1974;57: 383-394.
44. Sncdecor GW, Cochran WG: Statistical Methods. Ames. Iowa State University Press. 1980.
45. Bierman CW, Assem ESK, Mongar JL: Inhibition and stimulation of histamine release by ox-atomide. Int J Immunophannacol 1979:1:227-231.
46. Cavagni G, CalTarelli C, Giordano S, Romanini E, Bertolini P, Bcnvcnuti C: Pharmacokinetics of two oral liquid formulations of oxatomide in children. Int J Clin Pharmacol Ther Toxicol 1992:30:275-276.
47. Casolaro V, Spadaro G, Marone G: Human basophil relcasability. VI. Changes in basophil re-leasability in patients with allergic rhinitis or bronchial asthma. Am Rev Respir Dis 1990: 142:1108-1111.
48. Ruoss SJ, Hartmann T, Caughey GH: Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 1991:88:493-499.
49. Hartmann T, Ruoss SJ, Raymond W W, Suewen Caughey GH: Human tryptase as a potent, cell-specific mitogen: Role of signaling pathways in synergistic responses. Am J Physiol 1992:262: L528-L534.
50. Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF: Generation ofC3a ana-phylatoxin from human C3 by human mast cell tryptase. J Immunol 1993:130:1891-1895.
51. Samuelsson B, Dahlén SE, Lndgren JA, Rotizer CA, Serhan CN: Leukotricnes and lipoxins: Structures, biosynthesis, and biological effects. Science 1987:237:1171-1176.
52. Lam S, Chan H, LeRiche JC, Chan-Yeung Y, Salari H: Release of leukotriencs in patients with bronchial asthma. J Allergy Clin Immunol 1988:81:711-717.
53. 4-reccptor antagonist. N Engl J Med 1990;323:1736-1739.
54. Fauler J, Neumann C, Tsikas D, Frölich J: Enhanced synthesis of cysteinyl leukotriencs in psoriasis. J Invest Dermatol 1992;99:8-11.
55. MacGlashan DW, Botana LM: Biphasie Ca’ responses in human basophils. Evidence that the initial transient elevation associated w ith the mobilization of intracellular calcium is an insufficient signal for degranulation. J Immunol 1993;150:980-985.
56. Massey WA, Cohan VL, MacGlashan DW Jr, Gittlen SW, Kagey-Sobotka A, Lichtenstein LM. Warner JA: Protein kinase C modulates immunoglobulin E-mediated activation of human mast cells from lung and skin. I, Pharmacologic inhibition. J Pharmacol Exp Ther 1991: 258: 824-829.
57. 2+ store, in histamine release from rat peritoneal mast cell. Immunopharmacology 1991;21: 13-22.